Entrada Therapeutics Inc. has released a corporate presentation detailing its significant clinical momentum throughout 2025. The company anticipates having four active clinical programs by the end of the year, with notable advancements in its Duchenne muscular dystrophy (DMD) franchise. Clinical studies for ENTR-601-44 have been authorized in the UK, EU, and US, while ENTR-601-45 has been authorized in the UK and EU. Additionally, ENTR-601-50 is on track for global regulatory filings in the second half of 2025. Entrada is also advancing its preclinical pipeline, which includes programs targeting ocular diseases. The company maintains a strong financial position, with a cash balance of approximately $383 million, expected to support operations into the second quarter of 2027. You can access the full presentation through the link below.